Brazil Chronic Cough Therapeutics Market Analysis

Brazil Chronic Cough Therapeutics Market Executive Summary

Brazil Chronic Cough Therapeutics Market was valued at $158 Mn in 2022 and is estimated to reach $316 Mn in 2030, exhibiting a CAGR of 9.1% during the forecast period.

Chronic cough is a persistent cough that lasts for an extended period, typically defined as lasting for more than eight weeks. Unlike acute coughs, which are often associated with infections or other short-term conditions, chronic cough can be a symptom of an underlying and more persistent health issue. Common causes of chronic cough include respiratory conditions such as asthma, chronic obstructive pulmonary disease (COPD), gastroesophageal reflux disease (GERD), postnasal drip, and certain medications. It is important to identify and address the underlying cause of chronic cough through a thorough medical evaluation, as treating the root issue is crucial for effective management. Chronic cough can significantly impact an individual's quality of life and may require a multidisciplinary approach involving healthcare professionals such as pulmonologists, gastroenterologists, or ear, nose, and throat (ENT) specialists for comprehensive care.

The prevalence of chronic cough in Brazil is a notable health concern, with approximately 9.6% reported in the general population, displaying a slightly higher prevalence in males (9.6%) compared to females (8.6%). Concurrently, there is a substantial 17% prevalence of chronic obstructive pulmonary disease (COPD) in the country. These findings emphasize the widespread impact of chronic cough and the complex interplay of respiratory conditions in Brazil. Certain groups exhibit a higher prevalence, including older adults, with age being a significant risk factor, smokers, where tobacco use significantly increases the likelihood, and individuals with existing respiratory conditions such as asthma, COPD, and postnasal drip. The coexistence of chronic cough and COPD underscores the need for comprehensive strategies in addressing respiratory health issues.

Trevi Therapeutics has recently commenced two clinical trials for its investigative drug Haduvio aimed at addressing refractory chronic cough. The Phase IIa RIVER clinical trial is designed to assess the effectiveness and safety of Haduvio in reducing refractory chronic cough. Simultaneously, the Phase 2b CORAL clinical trial will investigate three different doses of Haduvio in comparison to a placebo for chronic cough in individuals with idiopathic pulmonary fibrosis (IPF). Earlier this year, Trevi Therapeutics shared positive findings from the Phase II CANAL trial, focusing on Haduvio's efficacy in challenging-to-treat patients with chronic coughs associated with IPF. The trial revealed that treatment with nalbuphine ER resulted in a rapid and substantial decrease in recorded daytime cough frequency.

Market Dynamics

Market Growth Drivers

Increasing Prevalence of Chronic Cough: The growing occurrence of chronic cough among the Brazilian populace stands out as a key factor propelling market growth. With enhanced awareness and improved diagnostic capabilities, an increasing number of individuals are actively pursuing treatment, leading to a heightened demand for therapeutics addressing chronic cough.

High Incidence of Respiratory Conditions: The increased occurrence of respiratory ailments like asthma, chronic obstructive pulmonary disease (COPD), and idiopathic pulmonary fibrosis (IPF) is a leading factor in the heightened frequency of chronic cough. As a result, there is a growing demand for therapeutics that specifically target these foundational respiratory issues, playing a pivotal role in propelling the expansion of the market.

Increasing Tobacco Use: The well-established connection between smoking and chronic cough has led to an increased demand for therapeutic solutions aimed at managing and relieving symptoms associated with chronic cough among a substantial portion of the population engaged in tobacco use.

Market Restraints

Limited Awareness and Diagnosis: A significant restraint lies in the limited awareness about chronic cough and its potential underlying causes among both the general public and healthcare professionals. This can result in delayed diagnosis and treatment initiation, hindering market growth.

Healthcare Infrastructure Challenges: Brazil faces challenges related to healthcare infrastructure, including uneven access to healthcare services across different regions. Unequal distribution of medical facilities can impede the timely diagnosis and management of chronic cough, acting as a restraint to market expansion.

Affordability and Accessibility Issues: Economic disparities and healthcare affordability concerns in Brazil may limit access to chronic cough therapeutics for certain segments of the population. Affordability issues can be a significant restraint, particularly in regions with lower socioeconomic status.

Healthcare Policies and Regulatory Landscape

In Brazil, the oversight of healthcare policies and regulations for therapeutic drugs is conducted by key entities, predominantly the National Health Surveillance Agency (ANVISA). ANVISA's primary responsibility is to guarantee the quality, safety, and effectiveness of pharmaceuticals. In conjunction with ANVISA, the Chamber of Medicines assesses the integration of new drugs into the public health system, while the Brazilian Health Regulatory Chamber (CMED) and the Brazilian Pharmaceutical Market Regulation Chamber contribute to the regulation of drug pricing. The Ministry of Health collaborates with ANVISA in formulating healthcare strategies and policies, with the National Cancer Institute (INCA) playing a pivotal role in shaping policies and guidelines related to cancer. The National Health Council (CNS) ensures community involvement in health-related decisions, and the National Commission for Ethics in Research (CONEP) oversees the ethical aspects of clinical trials.

Competitive Landscape

Key Players

• GlaxoSmithKline (GSK)
• Pfizer
• McNeil Consumer Healthcare (Johnson & Johnson)
• Procter & Gamble (P&G)
• Reckitt Benckiser Group
• Perrigo Company
• Medtech Products Inc.
• Bionpharma Inc.
• A. Vogel Canada Inc.
• Jamieson Laboratories